ICM
VIR icon

Islay Capital Management’s Vir Biotechnology VIR Stock Holding History

Islay Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,302
Closed -$110K – 287
2022
Q2 		$110K Buy
+4,302
New +$100K 0.11% 116

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Islay Capital Management's VIR Position: Q3 2022 in Review

Islay Capital Management sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 4,302 shares — an estimated $110K sold.

Islay Capital Management first reported a position in VIR in Q2 2022 and held it in 1 quarter. The position peaked at $110K in Q2 2022. 220 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Islay Capital Management reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Islay Capital Management sold 4,302 Vir Biotechnology shares in Q3 2022, an estimated $110K.
  • Islay Capital Management first reported a position in Vir Biotechnology in Q2 2022 and held it in 1 quarter.
  • Islay Capital Management's Vir Biotechnology position peaked at $110K in Q2 2022.
  • 220 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Islay Capital Management's 13F filing for Q3 2022, filed 21 Oct 2022.